Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country.
Nisreen AmayiriMaisa SwaidanAhmed IbrahimiNader HirmasAwni MusharbashEric BouffetMaysa Al HussainiVijay RamsawamiPublished in: JCO global oncology (2021)
Patients with SHH and group 4 medulloblastoma had excellent survival comparable with high-income countries. Compliance with treatment protocols and avoiding radiotherapy delays are important in achieving adequate survival in low- to middle-income country settings. Subgroup-driven treatment protocols should be considered in countries with limited resources.